Holen Sie sich die Stockscreener-App
0.6302
4.53%
-0.0299
Handel nachbörslich:
.64
0.0098
+1.56%
Enlivex Ltd Aktie (ENLV) Neueste Nachrichten
Enlivex Secures Australian Patent for Allocetra in Osteoarthritis Treatment - GuruFocus
Enlivex receives Australian patent for osteoarthritis treatment - Investing.com
Enlivex Announces Issuance of Australian Patent Covering the Use of Allocetra™ in Patients with Osteoarthritis - The Manila Times
ENLV Q4 2025 Earnings: Deep Losses and Clinical Progress Amid Severe EPS MissEarnings Revision Upgrade - newsline.com
Enlivex Therapeutics stock (IL0011283620): Data monitoring, Nasdaq notice and next steps for investo - AD HOC NEWS
ENLV Q4 2025 Earnings: Significant EPS Miss Reflects Clinical-Stage DevelopmentHigh Estimate Range - newsline.com
Number of shareholders of Enlivex Ltd. – LSX:A119KH - TradingView
RAIN Highlights $200M Ecosystem Commitment, $100M Liquidity Expansion, and World Cup Growth Strategy Ahead of Version 2 Launch - GlobeNewswire Inc.
ENLIVEX TO PRESENT QUALITY LONGEVITY MODEL POWERED BY PREDICTION MARKETS TREASURY AT PROOF OF TALK 2026 - marketscreener.com
Enlivex brings longevity‑prediction markets pitch to $18T Paris summit - Stock Titan
Enlivex to present knee osteoarthritis trial data at EULAR By Investing.com - Investing.com South Africa
Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026 - The Manila Times
Enlivex to present knee osteoarthritis trial data at EULAR - Investing.com
Experimental cell therapy eases knee arthritis pain for 6 months - Stock Titan
Enlivex Values RAIN Token Treasury at $1.16 Billion as Rain Protocol Climbs to No. 3 in Prediction Markets - The Globe and Mail
Enlivex (ENLV) Tests Key Support at $0.72 as Downtrend IntensifiesImbalance Zone - The Legal Advocate
Enlivex's RAIN tokens valued at $1.16B as Rain protocol ranks 3rd in global prediction markets. - Pluang
Enlivex reports $1.16 billion in RAIN token holdings - Investing.com UK
Enlivex reports $1.16 billion in RAIN token holdings By Investing.com - Investing.com India
Enlivex Highlights $100M Liquidity Boost for Rain as Treasury-Backed Prediction Market Enters Global Top Three - The Globe and Mail
Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.16 Billion; Rain Foundation Appoints Industry Leaders to Advisory Board - The Manila Times
RAIN treasury hits $1.16B as Enlivex (Nasdaq: ENLV) details prediction markets push - Stock Titan
Enlivex Ltd. (ENLV) Rallies 14%: Key Levels and Technical OutlookBPI Reversal - The Legal Advocate
Enlivex Highlights Rain Foundation's $100M Commitment - GuruFocus
Enlivex (NASDAQ: ENLV) details $100M Rain liquidity and massive RAIN token holdings - Stock Titan
Enlivex Treasury Portfolio Update: Rain Protocol Jumps Into Top Three Global Prediction Markets In League Table Following $100M In Additional Liquidity - marketscreener.com
$100M liquidity push lifts Rain into top 3 prediction markets - Stock Titan
Enlivex Surges 12.87% as Biotech Stock Breaks Above Key Support LevelsCTA Positioning - newsline.com
Enlivex (ENLV) Shares Slide 4.67% as Stock Tests Key Support at $0.65Ichimoku Entry - Newser
ENLV Q4 2025 Earnings: Significant EPS Miss Amid Development Stage CostsROE Trend Analysis - The Legal Advocate
Enlivex Ltd. (ENLV) Slides Slightly as Shares Hover Near Key Support LevelFast Moving Stocks - thelegaladvocate.com
Enlivex Ltd expected to post a loss of 2 cents a shareEarnings Preview - TradingView
Enlivex (ENLV) Edges Higher After Testing Key Support at $0.69Ichimoku TK Cross - Newser
ENLV Q1'26 Earnings: EPS estimate is (0.02) USD - TradingView
Enlivex Therapeutics Initiates Phase 2b Trial in US, Doses First Patient with Allocetra for Knee Osteoarthritis - geneonline.com
Enlivex Doses First US Patient in Phase 2b Knee Osteoarthritis Trial - Moomoo
Enlivex (ENLV) Begins Phase 2b Clinical Trial for Osteoarthritis Treatment - GuruFocus
Enlivex doses first U.S. patient in knee osteoarthritis trial - Investing.com UK
Enlivex doses first U.S. patient in knee osteoarthritis trial By Investing.com - Investing.com South Africa
Enlivex Doses First U.S. Patient in Phase 2b Allocetra Trial for Knee Osteoarthritis - TipRanks
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):